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Cyclophosphamide is a well-known cause of hemorrhagic cystitis. However, the best treatment for
hemorrhagic cystitis is still unknown. Herein, we present a patient with cyclophosphamide-induced
hemorrhagic cystitis. The patient had a history of myasthenia gravis and had received cyclophospha-
mide therapy for 14 years. He was admitted due to gross hematuria, which was initially treated by
cystoscopic fulguration, followed by continuous bladder irrigation. Due to refractory hemorrhaging,
fulguration was repeated and percutaneous suprapubic cystostomy was performed. The bladder hem-
orrhage eventually subsided after hyperbaric oxygen therapy and intravesical sodium hyaluronate
instillation. The combination of hyperbaric oxygen therapy and intravesical sodium hyaluronate instil-
lation may be useful in severe hemorrhagic cystitis caused by cyclophosphamide.
Copyright  2014, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Cyclophosphamide, an oxaphosphorine, is a well-known cause
of hemorrhagic cystitis. A urinary metabolite of cyclophosphamide,
acrolein, is believed to be responsible for hemorrhagic cystitis.1 The
best treatment for hemorrhagic cystitis is still unknown. Herein, we
present a patient with cyclophosphamide-induced intractable
hemorrhagic cystitis treated successfully after fulguration, hyper-
baric oxygenation (HBO), and intravesical sodium hyaluronate.2. Case report
A 62-year-old man had a history of thymoma with myasthenia
gravis. He had received a thymectomy 16 years previously and had
taken oral cyclophosphamide 25 mg daily for 14 years. Three years
prior to this admission, urothelial carcinoma of the urinary bladder,
with carcinoma in situ, was diagnosed at a local hospital.
The patient complained of intermittent gross hematuria for
several years, which progressed for 1 month. He visited a local
hospital, and abdominal computed tomography revealed diffusertment of Surgery, Taichung
Section 4, Taichung 40705,
).
ciation. Published by Elsevier Taiwthickening of the bladder wall with blood clots inside. He subse-
quently received cystoscopic fulguration at the local hospital.
However, repeated gross hematuria with blood clot-induced Foley
catheter obstruction occurred. In this case, massive blood trans-
fusion was also required due to anemia. He was then transferred to
our hospital.
Cystoscopic fulguration (Fig. 1) and a random bladder wall biopsy
were performed; the pathology report showed no malignancy.
However, severe hematuria was still noted despite continuous
bladder irrigationwith normal saline and intravenous mesna. Due to
the refractory bladder hemorrhage, fulgurationwas performed twice
on the 6th hospital day and 21st hospital day, and suprapubic cys-
tostomy was carried out to prevent bladder distension. The patient
had four sessions of HBO, at 1.5 bar for 90 minutes, during the
hospital stay. The bladder hemorrhage subsided, and he was dis-
charged on the 27th hospital day. In total, 22 units of packed red
blood cell were transfused. However, he still complained of inter-
mittent gross hematuria, and 1 month after discharge, cystoscopy
revealed sloughy bladder mucosa (Fig. 2). Another 10 sessions of
HBO and six cycles of intravesical sodium hyaluronate, 40 mg/50mL,
at an interval of 1 week were given. The gross hematuria gradually
subsided, although he still complained of voiding frequency (16e18
times in the day hours), urgency, and nocturia (4e5 times at night).
Four months after discharge, cystoscopy revealed no more oozing
from the bladder mucosa (Fig. 3). Erythematous mucosa was still
seen over the right lateral wall of the bladder; however, he no longeran LLC. Open access under CC BY-NC-ND license.
Fig. 1. Cystoscopic ﬁnding during the ﬁrst fulguration revealed diffused oozing of
bladder mucosa.
Fig. 3. Four months after discharge, erythematous lesions mostly subsided. Scar for-
mation was seen. There was no more oozing.
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frequency also improved with antimuscarinic treatment.3. Discussion
Cyclophosphamide is an immunosuppressive agent that is used
for systemic lupus erythematous, Wegener’s granulomatosis, and
rheumatoid arthritis. For myasthenia gravis, high-dose cyclophos-
phamide acts as an immunomodulator to “reboot” the immune
system by eliminating the mature immune system.2 The main toxic
effects include myelosuppression, hemorrhagic cystitis, alopecia,
and gonadal damage.3 Cyclophosphamide causes hemorrhagic
cystitis by renal excretion of its hepatic metabolite, acrolein, which
is urotoxic. The reported incidence of cyclophosphamide-induced
hemorrhagic cystitis ranges from 2% to 40%, and the average oral
dose of cyclophosphamide that causes hemorrhagic cystitis is re-
ported to be 90 g, with an average drugs usage duration of 38
months.4 The symptoms include gross hematuria, frequency,
dysuria, burning, urgency, incontinence, and nocturia, and they
may persist and reoccur for several years after stopping treatment.5
The best treatment for cyclophosphamide-induced hemorrhagic
cystitis is prevention. Mesna, which conjugates acrolein in urine, is
an effective prophylaxis against cyclophosphamide cystitis.6 Once
hemorrhagic cystitis develops, adequate hydration is usuallyFig. 2. One month after discharge, sloughy bladder mucosa was noted.sufﬁcient to prevent cystitis. Various treatments for hemorrhagic
cystitis have been applied for cyclophosphamide-induced hemor-
rhagic cystitis (Table 1).7 It can be treated with continuous saline
irrigation; acetylcysteine has been shown to bind acrolein and has
been used as a bladder instillation.8 Efﬁcacy of intravesical instil-
lation, with various substances including E-aminocaproic acid,
formalin, alum, phenol, silver nitrate, prostaglandin, ﬁbrin glue,
and sodium hyaluronate, in treating bladder hemorrhages have
been reported. In Miodosky et al’s9 study, 85% of the patients
responded partially or completely to sodium hyaluronate treat-
ment, by different mechanisms including inhibition of immune
complexes, adherence to polymorphonuclear cells, inhibition of
leukocyte migration, regulation of ﬁbroblast and endothelial cell
proliferation, and enhancement of connective tissue healing. HBO
has been tried in radiation-induced hemorrhagic cystitis and
applied to cyclophosphamide-induced hemorrhagic cystitis in a
few cases.10 Embolization or open ligation of the hypogastric ar-
teries is another available option. Surgery is the last resort in pa-
tients with intractable massive hematuria.
The present case received oral cyclophosphamide 25 mg daily
for 14 years, equal tomore than 120 g cumulative dose. This is much
more than the reported average dose of cyclophosphamide that
causes hemorrhagic cystitis. Moreover, he had been diagnosed with
urothelial carcinoma of the urinary bladder 3 years prior to this
presentation, which may also have been related to cyclophospha-
mide. During a nearly-1-month hospital stay, he received fulgura-
tion of the bladdermucosa three times and 14 sessions of HBOwere
given subsequently, and the hematuria gradually subsided. After
discharge, he was treated with weekly intravesical sodium hya-
luronate for six cycles, and the hemorrhagic cystitis had not
relapsed after 18 months of follow-up.Table 1
Treatment of hemorrhagic cystitis.7
Continuous bladder irrigation Cystoscopy and fulguration
Intravesical instillation Oral agents
E-aminocaproic acid Conjugated estrogens
Formalin Sodium pentosan
Alum Polysulfates
Phenol Intravenous vasopressin
Silver nitrate Hyperbaric oxygen therapy
Prostaglandin Embolization
Fibrin glue Cystectomy
Sodium hyaluronate
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be life threatening. Various treatments have been reported; how-
ever, there is as yet no gold standard of therapy. A combination of
different treatments that work by different mechanisms may in-
crease the success rate. We suggest that combined cystoscopic
fulguration (HBO and intravesical sodium hyaluronate) may be a
useful treatment option for cyclophosphamide-induced hemor-
rhagic cystitis.Conﬂicts of interest
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